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Abstract
Fungal infection is one of the most important causes of morbidity and
mortality in bone marrow transplant (BMT) recipients. The growing
incidence of these infections is related to several factors including
prolonged granulocytopenia, use of broad-spectrum antibiotics, con-
ditioning regimens, and use of immunosuppression to avoid graft-
versus-host disease (GvHD). In the present series, we report five cases
of invasive mold infections documented among 64 BMT recipients
undergoing fluconazole antifungal prophylaxis: 1) A strain of Sce-
dosporium prolificans was isolated from a skin lesion that developed
on day +72 after BMT in a chronic myeloid leukemic patient. 2)
Invasive pulmonary aspergillosis (Aspergillus fumigatus) was diag-
nosed on day +29 in a patient with a long period of hospitalization
before being transplanted for severe aplastic anemia. 3) A tumoral
lung lesion due to Rhizopus arrhizus (zygomycosis) was observed in
a transplanted patient who presented severe chronic GvHD. 4) A
tumoral lesion due to Aspergillus spp involving the 7th, 8th and 9th
right ribs and local soft tissue was diagnosed in a BMT patient on day
+110. 5) A patient with a history of Ph1-positive acute lymphocytic
leukemia exhibited a cerebral lesion on day +477 after receiving a
BMT during an episode of severe chronic GvHD. At that time, blood
and spinal fluid cultures yielded Fusarium sp. Opportunistic infec-
tions due to fungi other than Candida spp are becoming a major
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Fungal infection is one of the most im-
portant causes of mortality among immuno-
compromised patients, particularly those sub-
mitted to bone marrow transplantation
(BMT). The growing incidence of these in-
fections is related to several factors includ-
ing prolonged granulocytopenia, use of broad-
spectrum antibiotics, central venous access
devices, and chemotherapy and radiotherapy
protocols employed as conditioning regimens,
as well as immunosuppression to prevent
graft-versus-host disease (GvHD) (1-4).
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Candida spp and Aspergillus spp repre-
sent the most common agents of fungal in-
fections among patients submitted to BMT
(2,3,5-7). However, after the beginning of
fluconazole prophylaxis as a routine meas-
ure, a wide spectrum of fungal species have
emerged as opportunistic pathogens among
such patients (2,8,9). Consequently, infec-
tions due to non-Candida fungi should be
kept in mind as possible causes of systemic
infections during deep immunosuppression
after BMT, particularly when patients suffer
from GvHD (4,10,11). We describe five cases
of invasive and sustainable non-Candida
fungal infections among 64 allogeneic BMT
recipients. All of them received fluconazole
therapy during and after BMT.
Patients and Methods
Between August 1993 and July 1998, a
total of 64 BMT were performed at the He-
matology and Transfusion Service of Escola
Paulista de Medicina, UNIFESP, and at the
Hematology Service of Casa de Saúde Santa
Marcelina, São Paulo, SP, Brazil. Pre-trans-
plant hematological diseases of the patients
included 29 cases of chronic myeloid leuke-
mia (CML, 22 chronic, 3 accelerated and 4
in the blastic crisis phase), 10 cases of acute
myeloid leukemia (AML, 5 in the first com-
plete remission  phase, 2 in the second and 3
with relapsed AML), 12 cases of severe
aplastic anemia (SAA), 6 cases of acute
lymphocytic leukemia (ALL), 2 cases of non-
Hodgkin’s lymphoma, and 1 case each of
multiple myeloma and myelodysplastic syn-
drome/AREB-t. Three patients (2 SAA and
1 chronic CML) were submitted to a second
BMT. All donors had bone marrow har-
vested from the posterior/anterior iliac crests
of the pelvis using standard sterile tech-
niques. A minimal amount of 2 x 108 total
nucleated cells/kg recipient weight were col-
lected for each patient.
All patients received a daily 200-mg dose
of fluconazole for prophylaxis of fungal in-
fections from the first day of the condition-
ing regimen until day +100 after BMT. Pro-
phylaxis was delayed or reintroduced when-
ever GvHD was diagnosed. Unusual non-
Candida fungal infections occurred in five
patients whose clinical features are described
below (Table 1). Clinical and laboratory data
were collected by reviewing the patient
records. Fungal isolates were sent to a refer-
ence laboratory for further identification at
the species level based on the micromor-
phology of their colonies.
Results
It was possible to identify five cases of
mold infections and three cases due to Can-
dida sp among the 64 BMT patients evalu-
ated between August 1993 and July 1998.
All patients studied had received fluconazole
prophylactic therapy during the first 100
days after BMT or whenever there was evi-
dence of chronic GvHD. Two chronic CML
patients had yeast isolated from their
Hickman lines after engraftment. Both were
on fluconazole therapy and their blood cul-
tures grew C. albicans. They received paren-
teral daily doses of 1 mg/kg amphotericin B
for ten days in order to overcome their infec-
tions. The third episode of systemic Candida
infection was recorded in a patient with ac-
celerated CML. She had strains of C. tropi-
calis isolated from the mouth and gastrointes-
tinal tract two weeks after fluconazole with-
drawal (on day +40) due to multidrug hepa-
titis. Blood cultures yielded the same fungal
agent during a febrile non-granulocytopenic
episode documented on day +57 when anti-
fungal treatment was initiated. All
candidemias were promptly resolved by the
introduction of intravenous amphotericin B
therapy. Two of three candidemic episodes
were documented during the regimen of
fluconazole prophylaxis that was interrupted
before initiating amphotericin B therapy. The
following five reports present the major clini-
cal and laboratory characteristics of all the
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mold infections reported during the study
period.
Case reports
Case 1 - Scedosporium prolificans. A
42-year-old man diagnosed with chronic
phase CML received allogeneic BMT from a
human leukocyte antigen (HLA)-identical
brother (Table 1). On day +40, he developed
grade II acute GvHD and was initially treated
with 1 mg/kg prednisone. The prednisone
dose was tapered to 20 mg after day +60.
During steroid therapy, the patient devel-
oped insulin-dependent diabetes. On day +72,
he presented with a granulomatous skin le-
sion which showed fungal infection when
biopsied (Figure 1). At that time, his white
blood cell count was 3.5 x 109/l, absolute
neutrophil count was 2.4 x 109/l, and lym-
phocytes were 1 x 109/l. Tissue cultures from
a surgical biopsy yielded S. prolificans. Ini-
tially, he was treated with 1 mg kg-1 day-1
amphotericin B for three weeks, without any
clinical improvement. On day +116, ampho-
tericin B was switched to itraconazole at 600
mg/day for six months, followed by 100 mg/
day for one year. He evolved to chronic
hepatic GvHD and was maintained on 20
mg/day prednisone plus 200-300 mg/day
cyclosporin until day +180. Immunosuppres-
sion was tapered after day +180. His hepatic
GvHD remained under control with 10 mg of
prednisone during the first year of follow-
Table 1. Features of unusual fungal infections seen after bone marrow transplantation (BMT).
Patient Case 1 Case 2 Case 3 Case 4 Case 5
Disease/age (years) CML/42 SAA/13 AML/43 SAA/24 ALL/21
Conditioning regimen Bu (16) Cy (200) VP-16 (60) Cy (200) Cy (120)
(mg kg-1 day-1) Cy (120) ATG (90) TBI 1340 cGy ATG (90) TBI 1320 cGy
GvHD prophylaxis MTX + CsA MTX + CsA PRD + CsA MTX + CsA MTX + CsA
Engraftment Day +14 Day +21 Day +13 Day +24 Day +21
Acute GvHD GII/day +40 None GII/skin, liver None None
Chronic GvHD Present None Present None Present
Infection site Skin Lung Lung Bone (ribs), soft tissue CNS/sepsis
(agent)  (S. prolificans) (A. fumigatus) (R. arrhizus) (Aspergillus sp) (Fusarium sp)
Treatment AMB followed by ITR AMB followed by ITR AMB AMB plus ITR AMB plus fluconazole
Outcome Alive without Dead - Gram-positive Dead - disseminated Alive 44 months Dead - disseminated
(Karnofsky index) evidence of fungal pneumonia on day zygomycosis and after BMT, with fungal infection on
infection (K = 100%) +317 chronic GvHD on no signs of infections day +477
day +310 (K = 100%)
Autopsy Absence of Not authorized Not authorized
fungal infection
Risk factors PRD therapy, Six months PRD therapy, Double catheter PRD, CsA, Ig and
diabetes, hand inpatient care diabetes, acute GII insertion, PRD thalidomide therapy
surgery one year before BMT, and extensive therapy, sepsis for extensive chronic
before BMT, acute respiratory arrest chronic GvHD episode before GvHD and leukemia
GII and chronic at catheter insertion, BMT, pericardial relapse
GvHD PRD and CsA use effusion after BMT
before BMT
CML = chronic myeloid leukemia, SAA = severe aplastic anemia, AML = acute myeloid leukemia, ALL = acute lymphocytic leukemia, Bu =
busulphan, Cy = cyclophosphamide, ATG = anti-thymocytic globulin, VP-16 = etoposide, TBI = total body irradiation, MTX = methotrexate, CsA =
cyclosporine, PRD = prednisone, AMB = amphotericin B, ITR = itraconazole, Ig = polyclonal immunoglobulin, GvHD = graft-versus-host disease.
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up. Prednisone was discontinued after that
time. Currently, he has no evidence of fungal
skin lesion and presents only a local scar.
Case 2 - Aspergillus fumigatus. A 13-
year-old girl with SAA, initially treated with
prednisone and cyclosporin, had a long pe-
riod of hospitalization in an intensive care
unit before BMT, when she suffered from
multiple episodes of febrile granulocytope-
nia, receiving broad-spectrum antibiotic
therapy. At the time of a central catheter
insertion, she experienced a respiratory ar-
rest demanding mechanical ventilation. She
was submitted to HLA-identical sibling allo-
geneic BMT. A sustained engraftment was
seen since day +18. On day +29, she devel-
oped fever with negative blood cultures. A
chest X-ray and thoracic CT scan showed
bilateral condensation, initially misdiagnosed
as a bacterial infection. On day +40, typical
peripheral nodular lesions were observed in
both lungs (Figure 2). She was started on
amphotericin B until a total accumulated
dose of 2.5 g was achieved, when she devel-
oped irreversible renal tubular acidosis and
antifungal therapy was switched to itracona-
zole. Two thoracotomies were performed on
days +43 and +71 and A. fumigatus was
isolated from tissue cultures of both surgical
samples. She died on day +347 due to a
Gram-positive pulmonary infection. At au-
topsy, no fungal infection was seen.
Case 3 - Rhizopus arrhizus. A 43-year-
old man with myelomonocytic AML was
submitted to HLA-identical sibling alloge-
neic BMT during the second complete re-
mission phase. As a complication, he devel-
oped grade II skin and liver acute GvHD
treated with prednisone. Five months later,
he evolved to extensive chronic GvHD (liver,
skin, oral lichen planus and cutaneous scle-
roderma-like lesions) requiring 8 mg kg-1
day-1 cyclosporin and 60 mg/day prednisone.
He also received psoralen-ultraviolet A light
therapy and intravenous polyclonal immu-
noglobulin for three months with some im-
provement. On day +241, an apical left pul-
monary infiltrate was seen. Bronchoalveolar
lavage was negative. Empirical treatment for
tuberculosis was initiated at that time. De-
spite the therapy for tuberculosis, the lung
lesion became tumoral and the patient was
submitted to thoracotomy on day +296. Cul-
tures from surgical lung material grew R.
arrhizus (zygomycosis). Amphotericin B was
started at that time, but the patient died two
weeks later with progressive liver failure.
An autopsy was not authorized by the fam-
ily. The radiological and macroscopic fea-
tures of the fungal lesions are shown in
Figure 3.
Case 4 - Aspergillus sp. A 24-year-old
woman with SAA was initially treated with
prednisone without any clinical response.
Before BMT, she had an episode of Serratia
sp sepsis. Engraftment occurred on day +17.
After day +20, she experienced persistent
Figure 1. Case 1 (Scedosporium
prolificans). Skin lesion on the
third finger of the left hand (up-
per panel) and the correspond-
ing histopathology exhibiting
fungal infection (lower panel).
See white arrows in 1000X mag-
nification.
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pericardial effusion that was empirically
treated as tuberculosis during the following
six months. On day +50, she reported pain
on the 7th and 8th right ribs. Imaging tests
including technetium scintigraphy were nor-
mal. On day +110, a new CT scan was
performed and a tumoral lesion involving
the 7th, 8th and 9th right ribs and local soft
tissue was seen (Figure 4). At that time, a
technetium scintigraphy scan was also posi-
tive. A surgical resection of tumoral lesions
was performed. Culture screening of local
drainage samples and resected bone yielded
Aspergillus sp. Tissue sections did not show
fungal involvement. She had been treated
with daily doses of 1 mg/kg amphotericin B
plus 600 mg itraconazole since day +110. On
day +256, another surgical resection was
done due to relapse of lesions on the same
level of left ribs. New histological examina-
tions and cultures of these second resection
samples were negative for fungal infections.
Amphotericin B tapering was tried during
the next three months, but a remarkable wors-
ening of clinical and radiological findings as
well as an increased erythrocyte sedimenta-
tion rate was noted. She remained on treat-
ment with 1 mg/kg amphotericin B therapy
three times a week up to a total dose of 7 g in
combination with 600 mg daily itraconazole.
At present, she receives no treatment, CT
and technetium scintigraphy scans are nega-
tive and the erythrocyte sedimentation rate is
normal more than 44 months after BMT.
Case 5 - Fusarium sp. A 21-year-old man
initially misdiagnosed as a case of Ph1-posi-
tive undifferentiated acute leukemia was
treated with conventional doses of cytara-
bine plus doxorubicin in February 1997. In
May 1997, he had bone marrow relapse.
Morphological, immunophenotyping and
cytogenetic tests showed Ph1-positive ALL.
He was submitted to the BFM-AR/83 proto-
col entering complete remission. On Sep-
tember 1997, he received an HLA-identical
sibling allogeneic BMT. After day +100, he
experienced severe chronic GvHD that de-
Figure 2. Case 2 (Aspergillus
fumigatus). CT scan showing
pulmonary lesions on air cres-
cent, typical of invasive as-
pergillosis, involving both lungs.
Figure 3. Case 3 (Rhizopus arrhizus). Details of the lung tumoral lesion: chest X-ray (upper
panel),  CT scan (lower left panel), and macroscopy (lower right panel).
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manded prolonged use of cyclosporin, 60
mg prednisone daily, 800 mg of thalidomide
daily plus an immunoglobulin course of 6 g
a week. On day +370, a testicular relapse of
his leukemia was diagnosed. At that time,
thalidomide, cyclosporin and prednisone
were tapered, resulting in a remarkable in-
crease of hepatic and skin GvHD lesions, but
control of the relapse of leukemia through
the graft-versus-leukemia effect. On day
+471, he suffered from generalized seizure
episodes. A cranial CT scan demonstrated a
right parietal hyperdense lesion. On day +477,
he developed multiple organ failure. Cul-
tures from blood and CNS fluid yielded
Fusarium sp.
Discussion
In the present series, five of 64 patients
developed non-Candida fungal infections due
to the following agents: Aspergillus sp (2),
Fusarium sp (1), R. arrhizus (1) and S.
prolificans (1). It is important to emphasize
that the diagnosis of fungal infections was
supported by culture and histopathological
findings in four of the five cases reported.
The diagnosis of rib osteomyelitis due to
Aspergillus spp was based on the culture
results of resected bones and local drainage
samples as well as the clinical response to
antifungal therapy.
Aspergillus infections have been reported
in 3 to 7% of patients submitted to BMT and
represent the second most common fungal
infection among such patients. The other
three agents documented in our series are
less frequently reported and, consequently,
reliable data showing their real incidence
among BMT patients are lacking. In a series
of 1186 BMT patients, zygomycosis agents
caused only a 2% rate of non-Candida infec-
tions and no case of Scedosporium sp infec-
tion was documented, in contrast to a 70%
rate of Aspergillus sp infection (2,3,6,11-
13).
Recipients of allogenic bone marrow graft
present several particular risk factors for
developing fungal infections, including che-
motherapy before and during BMT (8), a
prolonged period of mucositis and neutrope-
nia (8), use of central venous catheters (3,5,
11), immunosuppressive therapy (2,5,14),
cytomegalovirus infection (1-3,5,12), and
development of GvHD (1-3,5,12,15). Of note,
the five cases of fungal infections presented
Figure 4. Case 4 (Aspergillus sp). The arrows show tumoral lesions involving right ribs
identified during technetium scintigraphy (upper panel) and CT scan (lower panel).
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here had several of the mentioned risk factors
for developing such infections (see Table 1).
In case 1, S. prolificans was isolated
from a subcutaneous lesion. S. prolificans is
an uncommon filamentous fungi that was
first described in humans in 1984. S. prolifi-
cans has been isolated from plants and some
domestic animals such as dogs and cats. In
humans it has been related to three different
clinical conditions: a) colonization, particu-
larly of the respiratory tract, b) superficial
and deep localized infections in immuno-
competent or immunocompromised patients,
and c) disseminated infections in immuno-
suppressed patients. Most of the patients
with invasive localized or disseminated in-
fections have AIDS, leukemia or lymphoma,
or are recipients of organ transplants. Infec-
tions due to S. prolificans are generally re-
fractory to antifungal therapy and the prog-
nosis of disseminated infection due to S.
prolificans is very poor (16-18).
Our patient infected with S. prolificans
had a history of trauma causing the amputa-
tion of the distal phalanx of the second finger
of the left hand, one year before being sub-
mitted to BMT. This operation may be con-
sidered the site of entry for this fungal path-
ogen. The fungal infection was observed
after he developed diabetes with prednisone
therapy and GvHD. The number of peripher-
al neutrophils and lymphocyte counts at the
onset of fungal infection was within the nor-
mal range for the BMT course. We did not
evaluate NK, CD4, CD29 or CD8 cells for
any of our patients. However, we postulated
that the association of steroid therapy with
acute and chronic GvHD leads to a  immuno-
suppression state and may have some influ-
ence on the evolution of fungal infection.
Regarding his clinical outcome, in view of
the usually unsuccessful antifungal therapy
of invasive infections due to S. prolificans, a
remarkable feature of this case was the clini-
cal improvement obtained with itraconazole
therapy.
Patient 2 exhibited numerous risk factors
for Aspergillus infection, including a long
period of hospitalization in the presence of a
hospital construction area, prednisone and
cyclosporin therapy. Early in the course of
invasive aspergillosis, chest radiographs and
sputum cultures are falsely negative and the
diagnosis of invasive aspergillus infection is
usually guided by findings of the chest CT
scan. The presence of nodules with the halo
sign or exhibiting the air crescent sign (as
demonstrated in Figure 2) are radiological
findings helpful for the diagnosis of invasive
pulmonary aspergillosis. However, consid-
ering that other agents may mimic such ra-
diological aspects, culture and histopathol-
ogy data are needed to define the diagnosis
of aspergillosis. The mortality of pulmonary
aspergillosis is very high, especially among
BMT patients. The patient was treated suc-
cessfully with amphotericin B and by surgi-
cal resections of lung lesions, followed by
long-term itraconazole maintenance treat-
ment, as advocated by several authors (3,4,10-
12,19,20).
Case 4 developed an unusual clinical
presentation of Aspergillus infection evolv-
ing soft tissue and ribs, near the outlet hole of
the Hickman line. She had a partial response
after antifungal therapy and surgical resec-
tion of the lesions. However, after discon-
tinuation of antifungal therapy, there was a
clinical relapse. At the time of the second
resection of new lesions, it was not possible
to demonstrate tissue invasion by the fun-
gus. However, we should emphasize that she
was on continuous antifungal therapy. Since
Aspergillus spp had been isolated previously
from two cultures, she was kept on ampho-
tericin B therapy for a long period of time,
with an accumulated dose of 7 g. At present,
she is no longer on antifungal therapy, with
no signs of infections. Based on literature
data and the outcome of the present patient,
it is possible to say that bone aspergillosis
has generally an unsuccessful outcome and
demands not only long periods of antifungal
drugs but also surgical resection of the le-
796
Braz J Med Biol Res 35(7) 2002
J.S.R. Oliveira et al.
sions (6,19-21).
Patient 3 had a pulmonary zygomycosis,
initially presenting as an upper lobe infiltrate
that was negative when cultured for fungal
isolates obtained by fiberoptic bronchoscopy
with bronchoalveolar lavage and from a
transbronchial biopsy. First, he was treated
empirically for tuberculosis due to previous
exposure to a family case of the disease.
After developing severe extensive chronic
GvHD and diabetes and receiving flucona-
zole and prednisone therapy, he evolved a
cavitary lung lesion of the upper left lobe
and was submitted to thoracotomy for surgi-
cal excision of the pulmonary lesion. Lung
tissue culture yielded R. arrhizus, a finding
compatible with the histological recognition
of large aseptate hyphae seen in the lung
sections. It is interesting to note that this
patient had a previous history of extensive
exposure to dusty material in his shoe shop.
Unfortunately, the diagnosis was delayed
due to misinterpretation of the first pulmo-
nary lesions and to the initial results ob-
tained by the bronchoalveolar lavage and the
transbronchial biopsy. Zygomycosis is one
of the most acute and fulminant fungal infec-
tions known and generally has a poor out-
come, especially among severely immuno-
compromised patients (9,14-17,22).
Case 5 exhibited a brain abscess due to
Fusarium sp, a soil saprophyte and plant
pathogen, which has been increasingly re-
ported as an opportunistic agent of dissemi-
nated infection among neutropenic patients.
The characteristic signs of this infection are
skin lesions, fungemia and multiorgan in-
volvement. This infection is usually refrac-
tory to all antifungal drug therapies and re-
covery of neutropenia is mandatory for clini-
cal resolution (23). Few data are available
about the involvement of the CNS by Fusa-
rium spp. A review of 83 cases of invasive
fusarial infections reported up to 1995
showed that only six (7%) patients had CNS
involvement. Brain abscess and meningitis
following systemic invasive fusariosis have
been reported (2,3,24). The patient did not
exhibit skin lesions, lung involvement or
neutropenia, but Fusarium sp was recovered
from blood and spinal fluid. Despite a high
dose of amphotericin B, the patient died. He
suffered from extensive chronic GvHD that
showed a marked worsening after tapering
the initial immunosuppression scheme, in
order to treat the testicular relapse. The in-
duction of a graft-versus-leukemia effect was
successful, although it impaired his basic
immunity due to the  extensive GvHD, ensu-
ing a fatal Fusarium sp infection (24).
Three episodes of Candida infections
were also documented for two of the other
59 patients in our series. Two chronic CML
patients had febrile episodes after the isola-
tion of yeast from the Hickman lines and
from blood cultures, and the fungal cultures
grew C. albicans. The third episode of
candidemia was preceded by the isolation of
C. tropicalis from oral and gastrointestinal
samples. At the time fluconazole was with-
drawn due to multidrug acute hepatitis. The
patient then suffered complication with
candidemia due to C. tropicalis. All three
patients had a successful outcome with am-
photericin B therapy. It is remarkable that
fluconazole prophylaxis indeed decreased
the incidence of Candida sp infections among
such risk patients (3-5,8,11). However, it
should be emphasized that such prophylaxis
cannot prevent other opportunistic fungal
infections, such as zygomycosis, aspergillo-
sis and Fusarium sp infections (4,8,25).
We also should mention that this uncon-
trolled study was conducted in the setting of
a developing country where social and eco-
nomic factors have a strong influence on
routine clinical care. Cost factors were con-
sidered by the clinical staff when they de-
cided to use 200 mg/day instead of 400 mg/
day fluconazole.
It is noteworthy that all eight episodes of
invasive infections in the present material
were diagnosed after the neutropenic post-
transplant period. The median time from
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transplant to the diagnosis of the fungal in-
fections was 138 days after BMT, ranging
from 29 to 471 days. A significant number of
fungal infections occurred late after BMT
and were associated with GvHD and its treat-
ment.
Finally, the occurrence of severe non-
Candida infections highly refractory to avail-
able antifungal drugs should alert the clini-
cians to the need to develop new strategies
for the prophylaxis and therapy of fungal
infections. Recently, several new antifungal
drugs have been tested in humans in devel-
oping countries, including a parenteral itra-
conazole formulation (Jansen Pharmaceuti-
cal, São Paulo, SP, Brazil), voriconazole
(Pfizer, Guarulhos, SP, Brazil), posaconazole
(Schering, São Paulo, SP, Brazil), ravucona-
zole (Bristol-Myers Squibb, São Paulo, SP,
Brazil), caspofungin (Merck Sharp & Dhome,
São Paulo, SP, Brazil) and FK463 (Fujisawa,
Deerfield, IL, USA). All of these compounds
are very active against Candida spp and
Aspergillus spp. Actually, voriconazole and
posaconazole have also demonstrated some
activity against isolates of Scedosporium spp
and Fusarium spp. Hopefully, all of these
drugs will enhance the clinician’s ability to
care for patients with invasive fungal infec-
tions (26).
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